A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving Ris-Rez and the other receiving topotecan.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby powyżej 18 roku życia lub pełnoletnie zgodnie z prawem.
- •Potwierdzony rak płuc typu SCLC w zaawansowanym stadium, który powrócił.
- •Otrzymałeś wcześniej 1 rodzaj terapii (na bazie platyny z inhibitorem PD-(L)1) i przeszedł ją przez co najmniej 2 cykle.
- •Przed rozpoczęciem badania miała miejsce przerwa od leczenia chemioterapią trwająca ponad 30 dni.
- •Badanie wykazało co najmniej jedną zmianę nowotworową podlegającą ocenie.
- •Jesteś w stanie podpisać zgodę na udział w badaniu i przestrzegać jego zasad.
- •Twój ogólny stan zdrowia pozwala na udział w badaniu (dobra funkcja narządów i sprawność według skali ECOG 0 lub 1).
✗ Disqualifies
- •Zdiagnozowany rak płuc SCLC o złożonej budowie lub przekształcony.
- •Rak płuc SCLC we wczesnym stadium (niezaawansowanym).
- •Otrzymano wcześniej terapię lekiem z grupy koniugatów przeciwciało-lek (ADC) z substancją hamującą TOPO1 lub leczenie skierowane przeciwko B7-H3.
- •Występują uczulenia na składniki leków badanych lub inne alergie, które mogą uniemożliwić udział.
- •Ciężkie, niekontrolowane lub aktywne choroby serca.
- •Występowały znaczące objawy krwawienia lub skłonność do krwawień w ciągu ostatniego miesiąca.
- •Aktywne infekcje wymagające leczenia lub zdiagnozowane zakażenie wirusem HIV.
- •Aktywne przerzuty do mózgu, które są objawowe lub postępują, albo inne przerzuty do ośrodkowego układu nerwowego.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (126)
GSK Investigational Site
Mar del Plata, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
GSK Investigational Site
Rosario, Argentina
GSK Investigational Site
Vicente López, Argentina
GSK Investigational Site
Blacktown, Australia
GSK Investigational Site
St Leonards, Australia
GSK Investigational Site
Nedlands, Australia
GSK Investigational Site
Barretos, Brazil
GSK Investigational Site
CuritibaPR, Brazil
GSK Investigational Site
Florianópolis, Brazil
GSK Investigational Site
Porto Alegre, Brazil
GSK Investigational Site
Porto Alegre, Brazil
GSK Investigational Site
Rio de Janeiro, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Pleven, Bulgaria
GSK Investigational Site
Plovdiv, Bulgaria
GSK Investigational Site
Rousse, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Ottawa, Canada
GSK Investigational Site
Toronto, Canada
GSK Investigational Site
Montreal, Canada
GSK Investigational Site
Montreal, Canada
GSK Investigational Site
Vaasa, Finland
GSK Investigational Site
Boulogne-Billancourt, France
GSK Investigational Site
Grenoble, France
GSK Investigational Site
Saint-Herblain, France
GSK Investigational Site
Karlsruhe, Germany
GSK Investigational Site
Augsburg, Germany
GSK Investigational Site
Chemnitz, Germany
GSK Investigational Site
Esslingen am Neckar, Germany
GSK Investigational Site
Löwenstein, Germany
GSK Investigational Site
Lübeck, Germany
GSK Investigational Site
München, Germany
GSK Investigational Site
Nuremberg, Germany
GSK Investigational Site
Stuttgart, Germany
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Heraklion, Greece
GSK Investigational Site
Pylaia Thessaloniki, Greece
GSK Investigational Site
Pylaia Thessaloniki, Greece
GSK Investigational Site
Budapest, Hungary
GSK Investigational Site
Farkasgyepű, Hungary
GSK Investigational Site
Gyöngyös, Hungary
GSK Investigational Site
Kecskemét, Hungary
GSK Investigational Site
Székesfehérvár, Hungary
GSK Investigational Site
Törökbálint, Hungary
GSK Investigational Site
Dublin, Ireland
GSK Investigational Site
Jerusalem, Israel
GSK Investigational Site
Tel Aviv, Israel
GSK Investigational Site
Bergamo, Italy
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Orbassano, Italy
GSK Investigational Site
Pisa, Italy
GSK Investigational Site
Siena, Italy
GSK Investigational Site
Verona, Italy
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Ishikawa, Japan
GSK Investigational Site
Kagoshima, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kochi, Japan
GSK Investigational Site
Kyoto, Japan
GSK Investigational Site
Mie, Japan
GSK Investigational Site
Miyagi, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Toyama, Japan
GSK Investigational Site
Guadajalara, Mexico
GSK Investigational Site
Mexico City, Mexico
GSK Investigational Site
Mexico City, Mexico
GSK Investigational Site
San Pedro Garza García, Mexico
GSK Investigational Site
Kielce, Poland
GSK Investigational Site
Lodz, Poland
GSK Investigational Site
Otwock, Poland
GSK Investigational Site
Poznan, Poland
GSK Investigational Site
Siedlce, Poland
GSK Investigational Site
Almada, Portugal
GSK Investigational Site
Guimarães, Portugal
GSK Investigational Site
Craiova Dolj, Romania
GSK Investigational Site
Cluj-Napoca, Romania
GSK Investigational Site
Craiova, Romania
GSK Investigational Site
Floreşti, Romania
GSK Investigational Site
Iași, Romania
GSK Investigational Site
Timișoara, Romania
GSK Investigational Site
Changwon, South Korea
GSK Investigational Site
Cheongju Chungcheongbuk-do, South Korea
GSK Investigational Site
Daegu, South Korea
GSK Investigational Site
Gyeonggi-do, South Korea
GSK Investigational Site
Seongnam-si Gyeonggi-do, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Suwon Gyeonggi-do, South Korea
GSK Investigational Site
Ulsan, South Korea
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
L'Hospitalet de Llobrega, Spain
GSK Investigational Site
Las Palmas de Gran Canar, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Santander, Spain
GSK Investigational Site
Stockholm, Sweden
GSK Investigational Site
Basel, Switzerland
GSK Investigational Site
Lausanne, Switzerland
GSK Investigational Site
Adana, Turkey (Türkiye)
GSK Investigational Site
Samsun, Turkey (Türkiye)
GSK Investigational Site
Ankara, Turkey (Türkiye)
GSK Investigational Site
Ankara, Turkey (Türkiye)
GSK Investigational Site
Ankara, Turkey (Türkiye)
GSK Investigational Site
Diyarbakır, Turkey (Türkiye)
GSK Investigational Site
Istanbul, Turkey (Türkiye)
GSK Investigational Site
Izmir, Turkey (Türkiye)
GSK Investigational Site
Izmir, Turkey (Türkiye)
GSK Investigational Site
London, United Kingdom
GSK Investigational Site
Portsmouth, United Kingdom
GSK Investigational Site
Truro, United Kingdom
Trial contact
US GSK Clinical Trials Call Center
EU GSK Clinical Trials Call Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.